Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Myriad Genetics, Inc.NASDAQ: MYGN
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$3M, compared with $13.6M a year earlier. Trailing-twelve-month financing cash flow was $47.6M.
Context
- Financing cash flow amounted to 7.8% of revenue in FY2025, up 6.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near -$3M or moves back toward the trailing-twelve-month quarterly average of $11.9M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 64.2M USD
- Year-over-year change
- +967.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.2M | +967.6% |
| FY2024 | 2024-12-31 | (7.4M) | -104.8% |
| FY2023 | 2023-12-31 | 152.9M | +2011.3% |
| FY2022 | 2022-12-31 | (8M) | +94.7% |
| FY2021 | 2021-12-31 | (150.6M) | — |
Financing Cash Flow vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's LTM Mar 2026 financing cash flow of $47.6M is the 7th largest of the 10 companies compared; the peer median is $24.21M.
- Its year-over-year change of +217.3% is the 3rd highest of 9, against a peer median of +56.6%.
- Financing cash flow amounts to 5.7% of revenue for MYGN, versus a peer median of 17.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $748.48M | +1272.6% | — | 58.5% | |
| LTM Jun 2026 | $376.41M | +18.3% | +12.5% | 17.9% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $326.54M | — | — | 82.2% |
| LTM Mar 2026 | $128.08M | -4.2% | +357.0% | 198.5% | |
| LTM Jun 2026 | $50.31M | +94.9% | -53.8% | 1.9% | |
| LTM Mar 2026 | $48.45M | +266.7% | -42.3% | 15.1% | |
| LTM Mar 2026 | $47.6M | +217.3% | — | 5.7% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $24.21M | -50.6% | -7.8% | 1242.3% |
| LTM Jun 2026 | $11.39M | -94.3% | — | 1.5% | |
| LTM Jun 2026 | $338K | +126.6% | — | 0.1% | |
| Peer median (excluding MYGN) | $24.21M | +56.6% | -7.8% | 17.9% | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.2M) | (112M) | (263.3M) | (127.3M) | (365.9M) |
| Depreciation & Amortization | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M |
| Deferred Income Tax | (34.7M) | (31.9M) | (600K) | (300K) | (32.4M) |
| Stock-Based Compensation | 36.3M | 38.1M | 40.7M | 49.8M | 35.2M |
| Change in Working Capital | 120.8M | (83.5M) | 27M | (54.4M) | (19.3M) |
| Accounts Receivables | (8.8M) | 7.7M | 3.8M | (8.7M) | 6.2M |
| Inventory | 1.6M | (2.9M) | (1.8M) | (6.2M) | (3.2M) |
| Accounts Payables | 9.2M | (3.5M) | (3.7M) | 4.7M | (1.4M) |
| Other Working Capital | 118.8M | (84.8M) | 28.7M | (44.2M) | (20.9M) |
| Other Non-Cash Items | (139.4M) | 30.3M | 23.4M | 62.3M | 21.1M |
| Operating Cash Flow | 18.6M | (106.3M) | (110.9M) | (8.7M) | 1.8M |
| Capital Expenditures | (18M) | (45.3M) | (73.3M) | (29.7M) | (15.6M) |
| Acquisitions (Net) | 379.1M | (57.2M) | 0 | 8.8M | 0 |
| Purchases of Investments | (147.8M) | (103.2M) | 0 | 0 | 0 |
| Sales of Investments | 61.1M | 128.2M | 105.2M | 9M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 274.4M | (77.5M) | 31.9M | (11.9M) | (27.4M) |
| Debt Repayment | (226.4M) | — | 39.8M | 100K | 75.9M |
| Common Stock Issued | 0 | 0 | 117.6M | 0 | 3.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75.8M | (8M) | (4.5M) | (7.5M) | (15M) |
| Financing Cash Flow | (150.6M) | (8M) | 152.9M | (7.4M) | 64.2M |
| Effect of Forex Changes | (600K) | (600K) | 600K | (1M) | 800K |
| Net Change in Cash | 141.8M | (192.4M) | 74.5M | (29M) | 39.4M |
| Free Cash Flow | 600K | (151.6M) | (184.2M) | (38.4M) | (13.8M) |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.